Market News AIOpen the app

Analysts changed their ratings and price targets for Sarepta Therapeutics, showing a new outlook on the company.

OpinionRead the original at moomoo.com
Neutral

Sarepta's analysts kept or moved their ratings to hold, though J.P. Morgan and Deutsche Bank raised price targets.

SRPT · Sarepta Therapeutics

AI read · Neutral

The AI's read

The higher targets from J.P. Morgan and Deutsche Bank point to more room for Sarepta's share price. But all three firms rate Sarepta at hold, so their views do not show strong confidence in a rise.

Get alerts for SRPT

Follow Sarepta Therapeutics (SRPT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for SRPT
Free on the App Store and Google Play, or on the web.